ORAL & BUCCAL POUCHES
Functional pouches are the fastest-growing delivery format in the industry and the one with the least settled regulatory ground. Whether a pouch is a supplement, a food, or a drug is not determined by what is in it. It is determined by where the active is intended to go, and most briefs have not decided that yet.
THE CLASSIFICATION QUESTION
Swallowed, or absorbed?
A product intended to be ingested and a product intended for absorption across the oral mucosa are different regulatory objects in every market we work in, even with an identical formula. Mucosal or sublingual delivery moves a product toward drug territory in most jurisdictions. Ingestion keeps it in the supplement or food frameworks. The distinction shows up in the formulation long before it shows up in the copy: pH, particle size, salt form and release profile all signal intent. A brand that formulates for mucosal absorption and then markets an ingestible supplement has built a classification problem into the product.
THE TECHNICAL PROBLEMS
01
Dose uniformity.
A pouch is a small, discrete, low-mass unit. Uniformity across pouches within a batch is a genuine manufacturing constraint, particularly at low active inclusion, and it is harder to achieve here than in a tablet or capsule.
02
The pouch material.
The nonwoven is not inert. Actives can migrate into it, moisture moves across it, and the material interacts with flavour and with the powder bed. Material selection is a formulation decision, not a packaging one.
03
pH and salivation.
Oral pH, buffering and salivary flow change the ionisation state of an active and therefore how much of it stays in the mouth. Formulating without controlling for this means the delivered dose is whatever the individual’s mouth decides.
04
Flavour, burn and tolerance.
Cooling agents, acids and some actives produce burn or irritation at levels that work fine in a beverage. Tolerance in the mouth is a much narrower window, and it interacts with how long a user keeps the pouch in.
WHAT WE DO
Classification determination for each intended market, based on formulation intent rather than marketing description.
Active selection, salt form and dose feasibility for the format.
Pouch material specification and compatibility assessment.
Dose uniformity strategy and release testing approach.
Flavour, pH and tolerance development.
Stability and moisture control specific to the format.
Claims boundary per market.
Contract manufacturer identification and qualification, since pouch equipment is not general-purpose supplement equipment.
THE ACTIVE DECIDES THE PATHWAY
Nicotine pouches.
Regulated as drugs or as tobacco products depending on the jurisdiction, with entirely separate approval pathways and enforcement postures from anything in the supplement space.
Caffeine and energy pouches.
The most commercially active category and the least settled. Classification depends on format, presentation and intended route, and in several markets no authorised product exists while products are sold anyway.
Vitamin and mineral pouches.
Closest to the supplement frameworks, but dose limits and permitted forms still vary by market, and the mucosal question does not go away.
Botanical and nootropic pouches.
Ingredient permissibility is the binding constraint, and novel food or new dietary ingredient status frequently applies before any format question is reached.
WHY KOMPETE
Most regulatory advice on pouches is written by people who have read the rules. We develop pouch and oral-delivery products, including reformulation work on existing commercial pouches and medicated oral formats. The technical constraints on this page are the ones we have hit, not the ones we have researched. Kompete is a registered Trading Partner with Health Canada’s NNHPD under company code 79873.
Send us the intended route, the active and the target markets. We will define the classification, the formulation constraints and the claims boundary side by side.